Your shopping cart is currently empty

Hydroxymethyl dasatinib (M24) is a benzylhydroxy metabolite of dasatinib that demonstrates potent antiproliferative activity with an IC50 value of 46.7 nM in K562 chronic myeloid leukemia cells, and is used in kinase inhibitor metabolism studies, structure–activity relationship analysis, and evaluation of active drug metabolites in leukemia research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | Hydroxymethyl dasatinib (M24) is a benzylhydroxy metabolite of dasatinib that demonstrates potent antiproliferative activity with an IC50 value of 46.7 nM in K562 chronic myeloid leukemia cells, and is used in kinase inhibitor metabolism studies, structure–activity relationship analysis, and evaluation of active drug metabolites in leukemia research. |
| Molecular Weight | 504.01 |
| Formula | C22H26ClN7O3S |
| Cas No. | 910297-58-4 |
| Smiles | O=C(NC=1C(Cl)=CC=CC1CO)C=2SC(=NC2)NC=3N=C(N=C(C3)N4CCN(CCO)CC4)C |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (198.41 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.